Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Welcome to this issue of touchREVIEWS in Neurology, where we explore significant advances in neurology, cognitive health, and wearable technology in the management of various chronic conditions. This issue brings together a collection of expert perspectives and research that spans innovative therapies, preventive strategies, and case studies, each offering critical insights for clinicians and researchers. […]

Heinz Reichmann, EAN 2021: OPTIPARK Study Findings

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 5th 2021

We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease.

The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.

Questions:

  1. Opicapone has been investigated in randomized clinical trials, can you please summarize the mode of action of Opicapone and the trial findings?
  2. It is valuable to complement trial data with clinical experience in the real world – what did the OPTIPARK study investigate and what were the key findings?
  3. How do you see these real-world data contributing to the use of Opicapone alongside levodopa-based drugs in routine practice for the management of Parkinson’s disease?

Disclosures: Professor Heinz Reichmann was acting on Advisory Boards and gave lectures and received research grants within the last 5 years from Bial, Desitin, Eisai, Kyowa-Kirin, Merz, Novartis, UCB Pharma and Zambon.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of the EAN Congress, Virtual 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup